StreetInsider.com News Articles

Leerink Reiterates Outperform Rating on Nuvalent (NUVL)

Wed, 03 Jun 2026 06:19:45 -0400

Leerink analyst Andrew Berens reiterated an Outperform rating and $165.00 price target on Nuvalent (NASDAQ: NUVL).

The analyst comments "We spoke with management after ASCO following the presentation of the ALKOVE-1 data and the 7-Yr CROWN followup (see previous note). In their view, the 7-Yr CROWN update is largely consistent with the 5-year update, leaving open whether lorlatinib can be tolerated by a majority of patients, especially those in non-academic centers. Management emphasized inconsistencies in the data suggesting that lorlatinib can be dose-reduced without any impact on efficacy, as well as the finding that most lorlatinib resistance mechanisms are not ALK

Nuvalent (NUVL) Reiterated at Overweight by Cantor Fitzgerald

Tue, 02 Jun 2026 07:26:44 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and $140.00 price target on Nuvalent (NASDAQ: NUVL).

The analyst commented, "CROWN data from lorlatinib are great, but it remains a tough drug to give. Friday's (5/29) big news was the long-term (83 mos follow-up) data from lorlatinib in 1L ALK-rearranged NSCLC, with PFS still not reached in the lorlatinib (TKI, PFE, N) arm. In our KOL's eyes, these data show that the ALK pathway can be blocked completely. However, he noted that lorlatinib's tolerability profile leaves room for improvement and that he sees a lot of progression in the real world.

Form 4 Nuvalent, Inc. For: May 28 Filed by: Noci Darlene

Mon, 01 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260601/26584307.html

Form 4 Nuvalent, Inc. For: May 28 Filed by: Noci Darlene

Mon, 01 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260601/26584307.html

Form 4 Nuvalent, Inc. For: May 28 Filed by: Miller Deborah Ann

Mon, 01 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260601/26584289.html

Form 4 Nuvalent, Inc. For: May 28 Filed by: Miller Deborah Ann

Mon, 01 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260601/26584289.html

Nuvalent (NUVL) Reiterated at Buy by Stifel on Ph1/2 ALKOVE-1 study Data

Mon, 01 Jun 2026 07:35:46 -0400

Stifel analyst Laura Prendergast reiterated a Buy rating and $135.00 price target on Nuvalent (NASDAQ: NUVL).

The analyst commented, "NUVL presented updated data from the Ph1/2 ALKOVE-1 study of neladalkib data at the annual 2026 ASCO meeting - see slides here - including first look at mPFS in pretreated patients. These data were presented in the same oral session as 7-year followup from PFE's Ph3 CROWN study of lorlatinib vs. crizotinib, both were followed by a discussion session.Earlier this week, NUVL announced the FDA accepted their NDA with priority review for neladalkib in TKI pre-treated ALK NSCLC patients; PDUFA date of

Nuvalent receives FDA priority review for cancer drug neladalkib

Wed, 27 May 2026 06:30:41 -0400

Nuvalent Inc. (NASDAQ: NUVL) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for neladalkib and granted it Priority Review with a target action date of November 27, 2026.

The application covers neladalkib for treatment of patients with tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer. The submission is based on data from the ALKOVE-1 Phase 1/2 clinical trial.

The company also announced that Georg Pirmin Meyer, M.D., has joined as Chief International Officer to lead global expansion efforts outside the United States.

Nuvalent now has New Drug Applications under FDA review for both neladalkib and

Nuvalent receives FDA priority review for cancer drug neladalkib

Wed, 27 May 2026 06:30:41 -0400

The company also announced that Georg Pirmin Meyer, M.D., has joined as Chief International Officer to lead global expansion efforts outside the United States.

Nuvalent now has New Drug Applications under FDA review for both neladalkib and

Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC